Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01384734 · ClinicalTrials.gov registry record · Phase 2
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
A Phase 2 study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 2
- Development phase
- 254
- Enrollment target
NCT01384734 is a Phase 2 study that has completed, run by ViiV Healthcare. The registered enrollment target is 254 participants.
The verdict
NCT01384734, a Phase 2 study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 254 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, efficacy, tolerability and pharmacokinetics of four doses of BMS-663068 with Raltegravir (RAL) + Tenofovir Disoproxil Fumarate (TDF). At least 1 dose of BMS-663068 can be identified which is safe, well tolerated, and efficacious when combined with RAL + TDF for treatment-experienced HIV-1 infected subjects. PHENOSENSE® is a registered trademark of Monogram Biosciences.
Interventions
- DRUG BMS-663068 400 mg
- DRUG BMS-663068 800 mg
- DRUG BMS-663068 600 mg
- DRUG BMS-663068 1200 mg
- DRUG Raltegravir 400 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 254 participants |
| Start Date | 2011-07-26 |
| Est. Completion | 2017-05-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01384734
The ClinicalTrials.gov registry entry for NCT01384734 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 254 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which BMS-663068 400 mg is the first listed.
NCT01384734 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01384734 about?
NCT01384734 is a clinical study titled "HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections". The purpose of this study is to assess the safety, efficacy, tolerability and pharmacokinetics of four doses of BMS-663068 with Raltegravir (RAL) + Tenofovir Disoproxil Fumarate (TDF). At least 1 dose of BMS-663068 can be identified which is safe, well tolerated, and efficacious when combined with R...
What is the current status of trial NCT01384734?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 254 participants. The study started on 2011-07-26. Estimated completion is 2017-05-12.
What interventions are being tested in trial NCT01384734?
The interventions under investigation include: BMS-663068 400 mg (DRUG), BMS-663068 800 mg (DRUG), BMS-663068 600 mg (DRUG), BMS-663068 1200 mg (DRUG), Raltegravir 400 mg (DRUG).
Who is sponsoring clinical trial NCT01384734?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.